tbuckley/cabot-search huggingface dataset:
THU0507 Evidence of The Use of Colchicine Are More Numerous in Cardiology and Hepato-Gastroenterology than in Rheumatology: A Systematic Literature Review of Clinical Trials
Authors: F. Kemta Lekpa, A.F. Kwimatouo Lekpa
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Colchicine has been used for millennia to treat acute gout flare, but numerous other conditions have been proposed for the use of this “<i>eau médicinale</i>”, including familial Mediterranean fever, Behçet9s disease and pericarditis. <h3>Objectives</h3> To investigate the efficacy and safety of colchicine whatever the indication. <h3>Methods</h3> A literature search of MEDLINE, EMBASE and Cochrane library databases was performed for human studies without language restriction from inception to January 2016, using the followings key-words: “colchicine”, “clinical trial”, “clinical controlled trials”, “randomized controlled trials”. We did not impose any date or language restrictions in the search. We also handsearched reference lists of identified studies. <h3>Results</h3> The process of selection of studies is presented in Figure 1. Of the 477 articles reviewed, 106 were analyzed including 77 randomized controlled trials, 2 nonrandomized controlled trials and 27 open studies. The subjects studied were chronic liver disease (n=13), primary biliary cirrhosis (n=11), post cardiac surgery syndromes (n=11), pericarditis (n=9), coronary syndromes and other heart disease (n=6), Familial Mediterranean fever (n=5), Behçet9s disease (n=5), amyloidosis (n=4), gout (n=3), knee osteoarthritis (n=3), constipation (n=3), lung fibrosis (n=3), psoriasis and psoriatic arthritis (n=3), asthma (n=3), primary sclerosing cholangitis (n=2), low back pain (n=2), proliferative vitreoretinopathy (n=2), recurrent aphthous stomatitis (n=2). Other indications have been evaluated in one clinical trial (Graves9 ophthalmopathy, oral mucositis during hematological malignancies, Peyronie9s disease, hidradinitis suppurativa, acne vulgaris, chronic bullous dermatosis, actinic keratosis, cutaneous leukocytoclastic vasculitis, finger clubbing and hypertrophic osteoarthropathy, pustulosis palmaris and plantaris, scleroderma, penile condylomata acuminate, mixed cryoglobulinemia, allergic rhinitis, delayed urticaria). Table 1 summarizes the main directions of colchicine in clinical trials. The most common adverse events were gastrointestinal intolerance. <h3>Conclusions</h3> Although acute gout is the major indication for use of colchicine, only 3 clinical trials are available for gout and no for other crystal-induced arthritis. Evidence are limited for knee osteoarthritis, low back pain and psoriatic arthritis. Clinical trials published are dominated by the treatement of heart diseases (especially pericarditis), systemic diseases (primary biliary cirrhosis, Familial Mediterranean fever, Behçet9s disease) and others chronic liver diseases. <h3>Disclosure of Interest</h3> None declared
Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.
Authors: Mohamed Sorror, Brenda M. Sandmaier, Barry Storer, Michael B. Maris, David G. Maloney, Rainer Storb
Journal: Blood (2006)
MHC class I–associated peptides derive from selective regions of the human genome
Authors: Hillary Pearson, Tariq Daouda, Diana Paola Granados, Chantal Durette, Eric Bonneil, Mathieu Courcelles, Anja Rodenbrock, Jean-Philippe Laverdure, Caroline Côté, Sylvie Mader, Sébastien Lemieux, Pierre Thibault, Claude Perreault
Journal: Journal of Clinical Investigation (2016)

MHC class I–associated peptides (MAPs) define the immune self for CD8+ T lymphocytes and are key targets of cancer immunosurveillance. Here, the goals of our work were to determine whether the entire set of protein-coding genes could generate MAPs and whether specific features influence the ability of discrete genes to generate MAPs. Using proteogenomics, we have identified 25,270 MAPs isolated from the B lymphocytes of 18 individuals who collectively expressed 27 high-frequency HLA-A,B allotypes. The entire MAP repertoire presented by these 27 allotypes covered only 10% of the exomic sequences expressed in B lymphocytes. Indeed, 41% of expressed protein-coding genes generated no MAPs, while 59% of genes generated up to 64 MAPs, often derived from adjacent regions and presented by different allotypes. We next identified several features of transcripts and proteins associated with efficient MAP production. From these data, we built a logistic regression model that predicts with good accuracy whether a gene generates MAPs. Our results show preferential selection of MAPs from a limited repertoire of proteins with distinctive features. The notion that the MHC class I immunopeptidome presents only a small fraction of the protein-coding genome for monitoring by the immune system has profound implications in autoimmunity and cancer immunology.
Long-Term Use of Low-Molecular-Weight Heparins (LMWH) for Cancer-Associated Venous Thromboembolism (VTE): Patients’ Perception in Tropique, a Prospective, Multicenter, Observational Study
Authors: Dominique Farge, Philippe Debourdeau, Norbert Claude Gorin, Anne Lamblin, Francis Cajfinger
Journal: Blood (2014)
Cardiac Mortality Among 200 000 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age
Authors: Katherine E. Henson, Raoul C. Reulen, David L. Winter, Chloe J. Bright, Miranda M. Fidler, Clare Frobisher, Joyeeta Guha, Kwok F. Wong, Julie Kelly, Angela B. Edgar, Martin G. McCabe, Jeremy Whelan, David J. Cutter, Sarah C. Darby, Mike M. Hawkins
Journal: Circulation (2016)

Background: Survivors of teenage and young adult cancer are acknowledged as understudied. Little is known about their long-term adverse health risks, particularly of cardiac disease that is increased in other cancer populations where cardiotoxic treatments have been used. Methods: The Teenage and Young Adult Cancer Survivor Study cohort comprises 200 945 5-year survivors of cancer diagnosed at 15 to 39 years of age in England and Wales from 1971 to 2006, and followed to 2014. Standardized mortality ratios, absolute excess risks, and cumulative risks were calculated. Results: Two thousand sixteen survivors died of cardiac disease. For all cancers combined, the standardized mortality ratios for all cardiac diseases combined was greatest for individuals diagnosed at 15 to 19 years of age (4.2; 95% confidence interval, 3.4–5.2) decreasing to 1.2 (95% confidence interval, 1.1–1.3) for individuals aged 35 to 39 years (2 P for trend &lt;0.0001). Similar patterns were observed for both standardized mortality ratios and absolute excess risks for ischemic heart disease, valvular heart disease, and cardiomyopathy. Survivors of Hodgkin lymphoma, acute myeloid leukaemia, genitourinary cancers other than bladder cancer, non-Hodgkin lymphoma, lung cancer, leukaemia other than acute myeloid, central nervous system tumour, cervical cancer, and breast cancer experienced 3.8, 2.7, 2.0, 1.7, 1.7, 1.6, 1.4, 1.3 and 1.2 times the number of cardiac deaths expected from the general population, respectively. Among survivors of Hodgkin lymphoma aged over 60 years, almost 30% of the total excess number of deaths observed were due to heart disease. Conclusions: This study of over 200 000 cancer survivors shows that age at cancer diagnosis was critical in determining subsequent cardiac mortality risk. For the first time, risk estimates of cardiac death after each cancer diagnosed between the ages of 15 and 39 years have been derived from a large population-based cohort with prolonged follow-up. The evidence here provides an initial basis for developing evidence-based follow-up guidelines.
The Time to Cytogenetic Response Determines Survival in CML Patients (Pts) Receiving Second-Line Tyrosine Kinase Inhibitors, and Allows Early Identification of Pts Destined To Fail Therapy.
Authors: Constantine S. Tam, Hagop Kantarjian, Gautam Borthakur, William Wierda, Farhad Ravandi, Susan O’Brien, Jenny Shan, Jorge Cortes
Journal: Blood (2007)
Valproic Acid Plus Retinoic Acid Induce Myeloid Differentiation in Chemotherapy-Resistant Acute Myeloid Leukemia Patients.
Authors: C. Nervi, F. Lo Coco, S. Minucci, A. Careddu tech., R. Fiorini, E. Finolezzi, N. Noguera, L. Travaglini, V. Gelmetti, D. Diverio, S. Fenu, M. Mancini, C. Tatarelli, M.A. Aloe Spiriti, M.C. Petti, G. Cimino, F. Mandelli, S. Amadori, P.G. Pelicci
Journal: Blood (2004)
Newly Developed ADAMTS13 Antigen Assay Reveals Marked Ethnic Differences and Depletion in Acquired Thrombotic Thrombocytopenic Purpura.
Authors: Hendrik B. Feys, Fang Liu, Ningzheng Dong, Inge Pareyn, Stephan Vauterin, Nele Vandeputte, Changgeng Ruan, Deckmyn Hans, Vanhoorelbeke Karen
Journal: Blood (2005)
AB0702 Medial Olivocochlear Reflex in Patients with Ankylosing Spondylitis
Authors: M. Serdaroğlu Beyazal, A. Özgür, S. Terzi, M. Çeliker, E. Dursun
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease. Via autoimmune mediators, AS can damage the auditory system similar to other systems. Otoacoustic emissions studies in patients with AS showed that the damage that causes hearing loss was in the outer hair cells. The medial olivocochlear (MOC) reflex is used to evaluate the medial olivocochlear efferent system (MOES), which includes the outer hair cells. <h3>Objectives</h3> The aim of this study was to evaluate the presence of subclinical damage in the inner ear with the aid of the MOC reflex test in patients with AS with no hearing complaints. <h3>Methods</h3> Thirty-four patients with AS and a control group of 30 healthy volunteers with similar demographic characteristics were evaluated in the study. Otoacoustic emission responses, MOC reflex results, and frequency-specific and total suppression findings were compared between the groups. The relationship between the clinical and laboratory findings for the patients with AS and the MOC reflex data were also investigated. <h3>Results</h3> Reduced MOC reflex response (<i>p</i>=0.04) and suppression (<i>p</i>=0.019) were detected in patients with AS. When the clinical and laboratory findings for the patients with AS and the MOC reflex test results were compared, a significant correlation was found only between the MOC reflex and the erythrocyte sedimentation rate (ESR). <h3>Conclusions</h3> The results showed that AS can damage the inner ear, especially the MOES, and can reduce the MOC reflex response without clinical hearing loss. <h3>References</h3> Amor-Dorado JC, Barreira-Fernandez MP, Vazquez-Rodriguez TR, et al (2011) Audiovestibular manifestations in patients with ankylosing spondylitis. Medicine (Baltimore) 90: 99–10 Papadimitraki ED, Kyrmizakis DE, Kritikos I, et al (2004) Ear-nose-throat manifestations of autoimmune rheumatic diseases. Clin Exp Rheumatol 22:485–494 Guinan JJ Jr (2010) Cochlear efferent innervation and function. Curr Opin Otolaryngol Head Neck Surg18: 447–453 <h3>Disclosure of Interest</h3> None declared
Management of toxicities and dose reduction/interruption of afatinib for EGFR mutated non-small cell lung cancer
Authors: Fumihiko Hirai, Shinichiro Shimamatsu, Gouji Toyokawa, Tsukihisa Yoshida, Kaname Nosaki, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose
Journal: Annals of Oncology (2015)
Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia
Authors: Qitian Mu, Qiuling Ma, Yungui Wang, Xiangmin Tong, Zhimei Chen, Jiyu Lou, Yizhi Cheng, Ying Lu, Wangmao Ni, Feifei Chen, Jie Jin
Journal: Blood (2011)
BMET-13CSF PROFILES AS PROGNOSTIC MARKER OR PREDICTIVE MARKER FOR INTRAVENTRICULAR CHEMOTHERAPY IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM SOLID CANCERS
Authors: Ho-Shin Gwak, Youngbo Shim, Sohee Kim, Jungnam Joo, Heon Yoo, Sang-Hoon Shin, None Seung, Hoon Lee
Journal: Neuro-Oncology (2015)

One of difficulties in intra-CSF chemotherapy for leptomeningeal carcinomatosis (LMC) is a lack of quantitative measure for the treatment response. Previous studies evaluated CSF profiles to predict treatment response or to correlate with prognosis. However, the results were inconsistent mainly due to small number of patients and heterogeneous treatment. We analyzed 283 patients with LMC from solid cancer, who underwent intraventricular chemotherapy at National Cancer Center from 2003 to 2013. CSF parameters were cytology, cell count and protein level. Control of intracranial pressure (ICP) was reviewed as an objective indicator of symptom improvement. CSF profiles before the treatment were significantly different according to sample sites (p < 0.001) in both cell count (lumbar vs. ventricular is mean 23 ± 44 vs. 8 ± 30) and protein level (mean 124 ± 168 vs. 33 ± 66 mg/dL). Initial lumbar CSF protein level was correlated with development of increased ICP (p = 0.059), hydrocephalus (HCP) (p = 0.049), and cauda equine syndrome (CES) (p< 0.001). But, initial ventricular CSF profiles did not reflect LMC disease activity. Decrease of CSF protein level after treatment was associated with increased ICP control (p = 0.017) while cell count change or cytology conversion is not predictive. Patients with low initial protein level (≤ 50mg/dL), or cell count (≤15) show prolonged survival (p = 0.001 and 0.015, respectively). But, decrease of either protein level or cell count after the treatment and cytology response did not significantly affect the patients OS. We suggest that CSF cell count is too low to reflect disease activity or treatment response especially those from ventricle. Initial CSF protein is in accordance with LMC symptoms and the decrease of protein level after the treatment is predictive of treatment response. We need new quantitative pharmacodynamic markers for LMC treatment to improve efficacy of intraventricular chemotherapy.
SP0062 Share Recommendations on Connective Tissue Diseases
Authors: M.W. Beresford
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Introduction</h3> The paediatric connective tissue disorders and paediatric systemic vasculitides are rare, complex and can lead to significant associated morbidity and mortality. Evidence-based guidelines are sparse and management is mostly based on physician experience. Consequently, treatment regimens differ widely throughout Europe. In 2013, a European initiative called SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) was launched to optimize and disseminate guidelines for diagnosis and management for children and young adults with paediatric rheumatic diseases (PRD) within Europe including the connective tissue disorders and vasculitides. <h3>Objectives</h3> To provide evidence-based recommendations for diagnosis and treatment of paediatric connective tissue disorders and systemic vasculitides. <h3>Methods</h3> Evidence based recommendations were developed using the European League Against Rheumatism (EULAR) standard operating procedure. International expert committees were instituted, consisting of paediatric rheumatologists with relevant expertise along with experts from other related disciplines. A detailed systematic literature review was undertaken, articles scored for validity and level of evidence. Recommendations derived from the literature were evaluated using an online survey, reformulated and discussed at a consensus meeting using the nominal group technique. Recommendations were accepted if more than 80% agreement is reached. <h3>Results</h3> Summary results of the systematic literature reviews overview of the final consensus SHARE recommendations will be presented. These provide evidence based, internationally agreed standards of minimal care for PRDs including the paediatric connective tissue disorders, rare as well as more common vasculitides. Specific detail will focus on childhood-onset systemic lupus erythematosus and the vasculitides. <h3>Conclusion</h3> The SHARE initiative provides recommendations for diagnosis and management treatment and thereby facilitates improvement and uniformity of care for patients throughout Europe. <h3>Disclosure of Interest</h3> None declared
Annals Consult Guys – In the Hot Seat: What Is This Rash After Low-Molecular-Weight Heparin?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2016)

Web Exclusives15 November 2016Annals Consult Guys – In the Hot Seat: What Is This Rash After Low-Molecular-Weight Heparin?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W16-0011 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Annals Consult Guys brings a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Janssen, Portola; Consultancies: Bristol-Myers Squibb, Janssen. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 November 2016Volume 165, Issue 10Page: CG1KeywordsDisclosureLow molecular weight heparinRashesResearch grantsResearch reporting guidelines ePublished: 15 November 2016 Issue Published: 15 November 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.Loading ...
Prohibitin Serves as a Novel Target Mitochondrial Protein of Phenyl-Chloroethyl Ureas Involved In Their Antiproliferative Effect on Multiple Myeloma Cells
Authors: Hye-Ran Kim, Ha-Young Eom, Dong Min Kim, Il-Chul Kim, Manian Rajesh Kumar, Sun-Woo Lee, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang, Myung-Geun Shin
Journal: Blood (2010)
Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.
Authors: Philippe Colombat, Nicole Brousse, Franck Morschhauser, Patricia Franchi-Rezgui, Pierre Soubeyran, Vincent Delwail, Eric Deconinck, Corinne Haioun, Charles Foussard, Catherine Sebban, Herve Tilly, Noel-Jean Milpied, Francois Boue, Jean-Michel Karsenti, Pierre Lederlin, Albert Najman, Catherine Thieblemont, Delphine Moreau, Loic Bergougnoux, Gilles Andre Salles, Philippe Solal-Celigny
Journal: Blood (2006)
Excess mortality in the myelodysplastic syndromes
Authors: Meritxell Nomdedeu, Arturo Pereira, Fernando Ramos, David Valcárcel, Dolors Costa, Montserrat Arnan, Xavier Calvo, Helena Pomares, Elisa Luño, María Díaz‐Campelo, Rosa Collado, Raquel de Paz, José‐Francisco Falantes, Carme Pedro, Josefa Marco, Itziar Oirtzabal, Joaquín Sánchez‐García, Mar Tormo, María‐Teresa Cedena, Benet Nomdedeu, Guillermo Sanz;
Journal: American Journal of Hematology (2016)

Abstract Myelodysplastic syndromes (MDS) are the commonest hematologic malignancies in the elderly. Since many patients with MDS actually die from age‐related ailments, the very disease burden of MDS remains largely unknown. This registry‐based study was aimed at investigating the excess mortality attributable to MDS. We analyzed 7,408 adult patients diagnosed with primary MDS from 1980 to 2014. Excess mortality was estimated by comparing the patients' survival with that expected in the matched general population. Median age of patients was 74 years, 58% were males, and 65% belonged to the lower risk categories of the Revised International Prognostic Scoring System (IPSS‐R). Excess mortality accounted for three‐fourths of the all‐cause mortality and was mainly driven by factors unrelated to leukemic transformation. Excess mortality increased with the IPSS‐R risk category [Incidence rate ratio (IRR): 2.1, 95% CI: 1.9–2.3; P &lt; .001]. Older age and male sex retained an independent association with higher excess mortality after discounting demographic effects. Excess mortality increased in the most recent periods just in the higher risk IPSS‐R categories (IRR: 1.2; 95% CI: 1.1–1.3 when comparing periods 2007–14, 2000–06, and 1980–99). In conclusion, MDS carry a significant excess mortality, even in the lower risk categories, that is mainly driven by factors unrelated to leukemic transformation, and increases with older age, male sex, and poorer risk categories. Excess mortality has increased in recent years in the higher risk patients, which might be ascribed to a parallel increase in age‐related comorbidities. Our results claim for more comprehensive treatment strategies for patients with MDS. Am. J. Hematol. 92:149–154, 2017. © 2016 Wiley Periodicals, Inc.
Levels of Mir-29b or Mir-101 Do Not Predict Response In Patients (pts) with Acute Myelogenous Leukemia (AML) Treated with the Combination of 5-Azacytidine, Valproic Acid and ATRA
Authors: Hui Yang, Zhihong Fang, Yue Wei, Yumin Hu, George Calin, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2010)
One-Year Post-Transplant Serum Ferritin Level Is a Predictor of Long-Term Survival Following Allogeneic Transplantation.
Authors: Stuart L Goldberg, Marc Elmann, Mark Kaminetzky, Eriene-Heidi Sidhom, Anthony R Mato, Jayshree Shah, Genique Stanislaus, Sora Limor, Alyona Weinstein, Elizabeth Jones, Kenneth Granholm, William Marrero, Katarzyna Szyperek, Ana L Polanco, Jamie L Yaniga, Michele Hanrahan, Theresa Amatucci, Pamela Sutherland, Phyllis McKiernan, Andrew L Pecora, Michele L Donato, Scott D Rowley
Journal: Blood (2010)
Prediction of Venous Thromboembolism in Patients with Cancer By the Activated Partial Thromboplastin Time: Results from the Vienna Cancer and Thrombosis Study
Authors: Cihan Ay, Florian Posch, Julia Riedl, Oliver Koenigsbruegge, Peter Quehenberger, Christoph Zielinski, Ingrid Pabinger
Journal: Blood (2015)
Mutation in the Nucleophosmin Gene (NPM1) Is a Stable Marker for Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Patients with Increased Sensitivity and Specificity Compared to Expression of the Wilms Tumor (WT1) Gene.
Authors: Thomas Kristensen, Birgitte Strange Preiss, Lone Friis, Michael B. Møller
Journal: Blood (2009)
Large Granular Lymphocyte Expansion Following Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with the Presence of CMV Reactivation and Probably with Acute GvHD and Shows An Indolent Outcome.
Authors: Sabine Nann, Alexander Tzankov, Nathan Cantoni, Jörg Halter, Dominik Heim, Dimitrios Tsakiris, Caroline Arber, Andreas Buser, Alois Gratwohl, Andre Tichelli, Alicia Rovo
Journal: Blood (2010)
Improving the Accuracy of BCR-ABL Transcript Quantitation: Pitfalls of Using a Common Standard for b3a2 and b2a2 Transcripts
Authors: Hanfang Zhang, Linda Fletcher, Niren Patel, Shanequa Bryant, Honglin Li, Ferdane Kutlar, Anand P. Jillella, Vamsi Kota, Betsy Clair, Abdullah Kutlar
Journal: Blood (2012)
Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100.
Authors: Aleah L. Smith, Joo Jungnam, Sheila Rao, Andreas Lundqvist, Lisa W. Cook, Rose S. Goodwin, Catalina Ramos, Nancy L. Geller, Richard W. Childs
Journal: Blood (2007)
The Hedgehog Regulated Transcription Factor and Tumor Suppressor, Gli3, Regulates Hematopoietic Stem Cell Number, Self-Renewal and Differentiation
Authors: Parvesh Chaudhry, Mohan Singh, Amy R McManus, Aparna Jorapur, Stephen James Capone, Giridharan Ramsingh, Akil Merchant
Journal: Blood (2015)
Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials
Authors: Maria Luisa Guerrera, Marzia Varettoni, Alessandra Tedeschi, Anna Maria Frustaci, Virginia Valeria Ferretti, Luca Arcaini, Paola Picardi, Silvia Zibellini, Sara Rattotti, Roberto Cairoli, Mario Cazzola
Journal: Blood (2015)